Work

Pharmacokinetics, tissue residue depletion and withdrawal period estimation for tylosin in geese (Anser anser domesticus) following intravenous, intramuscular, and oral administration

Year: 2026

Type: article

Abstract: Tylosin, a macrolide antibiotic, is used in poultry to treat Mycoplasma-associated respiratory disease and Clostridium perfringens-associated necrotic enteritis. To the authors' knowledge, no pharmacokinetic or tissue residue data exist for geese, preventing the establishment of a species-specific withdrawal period. This study characterized plasma pharmacokinetics in sixteen healthy adult male Bilgorajska geese (Anser anser domesticus) using a four-period crossover design following intravenous (5 mg/kg), intramuscular (25 mg/kg), single-dose oral (100 mg/kg), and multiple-dose oral (100 mg/kg bw/day for 3 consecutive days) administration. Tylosin concentrations were quantified via validated UHPLC-MS/MS method and analyzed using non-compartmental methods. Tissue residue depletion in muscle, fat, liver, and kidney was assessed in a separate group of sixteen geese at 10, 24, 48, and 72 h post-final oral dose, with withdrawal periods estimated using EMA WT 1.4 (MRL = 100 µg/kg). Systemic clearance was 0.81 ± 0.11 L/h/kg bw, volume of distribution 2.36 ± 0.12 L/kg bw, and terminal half-life approximately 2 h across parenteral routes. Absolute bioavailability was 57 ± 14% and 15-16% after intramuscular and oral dosing, respectively. No accumulation occurred after three days of oral administration. Liver residues were highest and most persistent; muscle and fat were below MRL value by 24 h, while kidney marginally exceeded MRL value at 72 h. Estimated withdrawal periods were 2.91, 4.23, and 7.66 days for muscle, kidney, and liver, respectively, yielding a provisional withdrawal period of 8 days following oral administration of tylosin at 100 mg/kg bw/day for 3 consecutive days. These exploratory findings provide the first species-specific pharmacokinetic and residue data for tylosin in geese, identifying liver as the limiting tissue and demonstrating route-dependent bioavailability.

Source: Veterinary Research Communications

DOI: 10.1007/s11259-026-11612-7